RT Journal Article
SR Electronic
T1 Development and validation of a nomogram for predicting overall survival of patients with ischemic cardiomyopathy and heart failure: a post-hoc analysis of the Surgical Treatments for Ischemic Heart Failure (STICH) trail
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.04.23296574
DO 10.1101/2023.10.04.23296574
A1 Guo, Pengju
A1 He, Chang
A1 Li, Junlei
A1 Jiang, Youxu
A1 Wang, Feng
A1 Wang, Jiaxiang
A1 Lin, Bin
A1 Feng, Deguang
YR 2023
UL http://medrxiv.org/content/early/2023/10/05/2023.10.04.23296574.abstract
AB Purpose To establish a nomogram for predicting the overall survival (OS) of patients with ischemic cardiomyopathy and heart failure based on the Surgical Treatment for Ischemic Heart Failure (STICH) trail.Methods Patients who had valid key variables in the hypothesis 1 were included and randomly divided into the training and validation groups (7:3 ratio). Using Cox proportional hazards model, predictors for the OS in training group were identified and integrated to establish a nomogram for predicting 1-year, 3-year, 5-year, and ten-year survival probability. The nomogram performance was evaluated using Harrell’s concordance index (C-index), time-dependent receiver operating characteristic curve, decision curve analysis, and Kaplan-Meier survival analysis.Results 940 of 1212 patients who had valid key variables were included. Seven predictors, including treatment type, gender, estimated glomerular filtration rate, Charlson co-morbidity index, 6-minute walk, end-systolic volume index and mitral regurgitation class were identified to establish the nomogram. The C-indices of the nomogram were 0.641 (95% CI: 0.627-0.655) and 0.649 (95% CI: 0.627-0.671) for training and validation groups, respectively. The calibration curves revealed consistency between predicted and observed survival. The area under 1-year, 3-year, 5-year, and ten-year OS receiver operating characteristic curves were 0.634, 0.616, 0.630 and 0.638 in the training group, respectively. Decision curve analysis showed effective net benefits of the model in clinical decision-making. Divided by the cutoff values of prognostic indices, low-risk patients showed better OS than those with high risk in training and validation groups (both p < 0.0001).Conclusion The current nomogram can effectively predict the OS of patients with ischemic cardiomyopathy and heart failure, provide information about multidisciplinary therapeutic that may prolong the survival time, and serve as a perfect tool in conjunction with the STS and EuroSCORE II risk models in clinical decision making.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNone.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:1. The National Heart, Lung, and Blood Institute 2. The Ethics Committee of Scientific Research and Clinical Trial, the First Affiliated Hospital of Zhengzhou UniversityI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data can be accessed via the Biologic Specimen and Data Repository Information Coordinating Center after the approval of the National Heart, Lung, and Blood Institute. https://biolincc.nhlbi.nih.gov OSoverall survivalICMischemic cardiomyopathyCABGcoronary artery bypass graftingPCIpercutaneous coronary interventionLVEFleft ventricular ejection fractionCADcoronary artery diseaseNYHANew York Heart AssociationMRmitral regurgitationESVIend-systolic volume indexeGFRestimated glomerular filtration rateCKD-EPIChronic Kidney Disease Epidemiology CollaborationCCICharlson co-morbidity indexMEDmedicalIQRinterquartile rangeROCreceiver operating characteristicDCADecision Curve AnalysisHRhazards ratioCIconfidence intervalAUCarea under curve